Abstracts tagged "Outcome measures"

Abstract Number: 0209 • ACR Convergence 2022
Sensitivity of Three Skin-Specific Efficacy Outcomes to Detect Patient- and Physician-Reported Improvement in Overall Skin Disease in Dermatomyositis
Josh Dan¹, Grant Sprow², Josef Concha³, Nilesh Kodali⁴, DeAnna Diaz⁵, Thomas Vazquez⁶, Felix Chin⁷, Barbara White⁸ and Victoria Werth³, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ²Albert Einstein College of Medicine, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴New Jersey Medical School, Coppell, TX, ⁵Philadelphia College of Medicine, Philadelphia, PA, ⁶FIU Wertheim College of Medicine, Virginia Beach, VA, ⁷University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁸SFJ Pharmaceuticals, Towson, MD
Background/Purpose: Variations of the Investigator Global Assessment (IGA) of overall skin disease have been successfully used as a primary efficacy endpoint in registrational clinical trials…
Abstract Number: 0502 • ACR Convergence 2022
The Effect of Osteoporosis on Developing Vertebral Compression Fracture After Single-level Posterior Lumbar Fusion Surgery: A Large Healthcare Claims Database Study
Vartika Kesarwani¹, Sean Esmende², Regina Kostyun², Matthew Solomito², Heeren Makanji², John Magaldi² and Mandeep Kumar², ¹University of Connecticut, Farmington, CT, ²Bone and Joint Institute, Hartford Hospital, Hartford, CT
Background/Purpose: Vertebral compression fracture (VCF) is a significant osteoporosis-related complication (ORC) associated with instrumented spinal fusion. Various studies have assessed the development of VCF in…
Abstract Number: 1026 • ACR Convergence 2022
Responsiveness and Minimal Clinically Important Difference in Patient-Reported Outcome Measures Among Patients with Psoriatic Arthritis
Paras Karmacharya¹, Courtney Stull², Alisa Stephens-Shields³, M. Elaine Husni⁴, Jose Scher⁵, Ethan Craig⁶, Robert Fitzsimmons³, Soumya Reddy⁷, Marina Magrey⁸, Alexis Ogdie⁹ and Jessica Walsh¹⁰, ¹Vanderbilt University, Nashville, TN, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pennsylvania, Philadelphia, ⁴Cleveland Clinic, Cleveland, OH, ⁵New York University School of Medicine, New York, NY, ⁶University of Pennsylvania, Wallingford, PA, ⁷NYU School of Medicine, New York, NY, ⁸Case Western Reserve University, University Hospitals, Richfield, OH, ⁹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ¹⁰University of Utah, Salt Lake City, UT
Background/Purpose: Despite significant heterogeneity in psoriatic arthritis (PsA), randomized controlled trials (RCTs) generally enroll a homogenous subgroup of PsA patients (polyarticular similar to rheumatoid arthritis).…
Abstract Number: 1343 • ACR Convergence 2022
Satisfaction with Rheumatoid Arthritis Care Is Related to Discordance with Providers’ Treatment Goals and Patients’ Reasons for Disagreement
Kelly O'Neill¹, Pamela Sinicrope², Cynthia Crowson³, Kathryne Marks⁴, Rachel Giblon⁵, Elena Myasoedova² and John Davis², ¹Rheumatoid Patient Foundation, Winter Springs, FL, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Eyota, MN, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: We previously reported on the incidence of shared treatment goal discussions which are associated with disease activity (DA) improvement and satisfaction within rheumatology care.…
Abstract Number: 1628 • ACR Convergence 2022
The Sjogren Tool for Assessing Response (STAR): Assessment of Response Rates Overall, According to Baseline Activity and by Domain: Reanalysis of 9 Clinical Trials in Primary Sjogren Syndrome
Raphaèle Seror¹, Gabriel Baron², Divi CORNEC³, Elodie Perrodeau², Marine Camus⁴, Professor Simon Bowman⁵, Michele Bombardieri⁶, Hendrika Bootsma⁷, Suzanne Arends⁷, jacques-eric gottenberg⁸, Benjamin A. Fisher⁹, Wolfgang Hueber¹⁰, Joel Van Roon¹¹, Valerie Devauchelle¹², Liseth de Wolff¹³, Peter Gergely¹⁴, Xavier Mariette¹⁵ and Raphaël Porcher¹⁶, ¹University Hospital Paris-Saclay, Le Kremlin Bicêtre, France, ²AP-HP Hôtel Dieu Hospital, Université Paris Descartes, Paris, France, ³CHRU Brest, Brest, France, ⁴Department of Rheumatology, Université Paris-Saclay, APHP Hôpital Bicêtre, Le Kremlin Bicêtre, France, ⁵University Hospitals Birmingham, Birmingham, United Kingdom, ⁶Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University, London, United Kingdom, ⁷University Medical Center Groningen, Groningen, Netherlands, ⁸Strasbourg University Hospital, Strasbourg, France, ⁹University of Birmingham, Birmingham, United Kingdom, ¹⁰Novartis Pharmaceuticals, Basel, Switzerland, ¹¹Rheumatology & Clinical Immunology, University of Utrecht, Utrecht, Netherlands, ¹²Université de Bretagne Occidentale, Brest, France, ¹³UMCG, Zwolle, Netherlands, ¹⁴Novartis Pharma, Basel, Switzerland, ¹⁵Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ¹⁶Université Paris Cité, Hôtel-Dieu, Paris, France
Background/Purpose: The ESSDAI and ESSPRI, used alone, are not able to capture all features of primary Sjögren's syndrome (pSS). The NECESSITY consortium developed the Sjögren's…
Abstract Number: 2012 • ACR Convergence 2022
Predictors of Remission in Rheumatoid Arthritis Patients Treated with Biologics: A Systematic Review and Meta-analysis
Yasmin Khader, Azizullah Beran, Sami Ghazaleh, Rawish Fatima, Ashu Acharya and Nezam Altorok, University of Toledo, Toledo, OH
Background/Purpose: Biologic disease-modifying antirheumatic drugs (bDMARDs) have emerged as an effective treatment of rheumatoid arthritis (RA), improving patients’ quality of life throughout the disease course.…
Abstract Number: 2235 • ACR Convergence 2022
Clinical Impact of a Digital Behavioral Therapy for Fibromyalgia Management in a Decentralized Trial
Yifei Dai¹, Michael Rosenbluth², Michael Gendreau³, Nicolette Vega⁴, Zunera Ghalib⁴, Allison Kraus⁴ and Brian Keefe⁵, ¹Swing Therapeutics, Gainesville, FL, ²Swing Therapeutics, San Francisco, CA, ³GENDREAU CONSULTING, LLC, Poway, CA, ⁴Swing Therapeutics, San Francisco, ⁵Swing Therapeutics, New York, NY
Background/Purpose: Cognitive behavioral therapy (CBT) has demonstrated level 1A evidence for management of fibromyalgia (FM). Acceptance and Commitment Therapy (ACT), a form of CBT, has…
Abstract Number: 0210 • ACR Convergence 2022
Themes in Patients’ Discordance with Provider’s Rheumatoid Arthritis Treatment Goals Relate to Patient Age, Gender, and Ethnicity
Kelly O'Neill¹, Pamela Sinicrope², Cynthia Crowson³, Kathryne Marks⁴, Rachel Giblon⁵, Elena Myasoedova² and John Davis², ¹Rheumatoid Patient Foundation, Winter Springs, FL, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Eyota, MN, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: We previously reported on themes in patients' treatment goals and their association with rheumatoid arthritis (RA) disease activity (DA) and aspects of rheumatology care,…
Abstract Number: 0516 • ACR Convergence 2022
Identifying Current Assessment and Treatment Strategies in Juvenile Systemic Sclerosis: An International Effort to Improve Patient Outcomes
Natalia Vasquez Canizares¹, Clare Pain², Marinka Twilt³, Amra Adrovic Yildiz⁴, Simone Appenzeller⁵, Edoardo Marrani⁶, Emanuela Del Giudice⁷, Antonella Petaccia⁸, Francesca Tirelli⁹, Gabriele Simonini¹⁰, Marco Cattalini¹¹, Ozgur Kasapcopur¹², Raju Khubchandani¹³, Kathryn Torok¹⁴, Betul Sozeri¹⁵, Biagio Castaldi¹⁶, Katherine Clarke¹⁷, Phuoc Duong¹⁷, Aybuke Gunalp¹⁸, meiping lu¹⁹, Hanna Lythgoe², Amanda Robinson¹⁴, Lauren Robinson²⁰, Paulo Rogerio Julio²¹, Susan Shenoi²², Emily Willis²³, Mustafa Çakan¹⁵, Valentina Leone²⁴, Rongjun Zheng¹⁹, Phillip Lawrence¹⁷, Franziska Rosser²⁵, Sarah Mayell², Lusine Ambartsumyan²⁶, Aurelia Minuti²⁷, Francesco Zulian²⁸ and Suzanne Li²⁹, ¹Children's Hospital at Montefiore/ Albert Einstein College of Medicine, New York, NY, ²Alder Hey Children’s NHS Foundation Trust, Liverpool, United Kingdom, ³Alberta Children's Hospital, Calgary, AB, Canada, ⁴School of Medicine, KOC University, Istanbul, Turkey, ⁵Unicamp, Campinas, São Paulo, Brazil, ⁶AOU Meyer, Florence, Italy, ⁷Sapienza University of Rome, Pediatric and Neonatology Unit, Maternal and Child Department, Rome, Italy, ⁸Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ⁹Women's and Child's Health, University Hospital of Padova, Padova, Italy, ¹⁰Meyer Children's Hospital, Florence, Italy, ¹¹Pediatric Clinic, University of Brescia, Brescia, Italy, ¹²Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Istanbul, Turkey, ¹³SRCC Children's Hospital, Mumbai, India, ¹⁴Pediatric Rheumatology, Children's Hospital of UPMC, Pittsburgh, PA, ¹⁵University of Health Sciences, Istanbul, Turkey, ¹⁶Women's and Child's Health, University Hospital of Padova, Padua, Italy, ¹⁷Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ¹⁸Istanbul University Cerrahpaşa Medical School, Istanbul, Turkey, ¹⁹Children’s Hospital of Zhejiang University Medical School, Zhejiang, China, ²⁰Hospital for Special Surgery, New York, NY, ²¹University of Campinas, Campinas, São Paulo, Brazil, ²²Seattle Children's Hospital and Research Center / University of Washington, Seattle, WA, ²³Royal Manchester Children’s Hospital, Manchester, United Kingdom, ²⁴Ismett, UPMC, Palermo, Italy, ²⁵University of Pittsburgh, Children’s Hospital of UPMC, Pittsburgh, PA, ²⁶Seattle Children's Hospital, University of Washington, Seattle, WA, ²⁷D. Samuel Gottesman Library Research and Education, Albert Einstein College of Medicine, Bronx, NY, ²⁸University of Padua, Padua, Italy, ²⁹Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, West Orange, NJ
Background/Purpose: Juvenile Systemic Sclerosis (jSSc) is an autoimmune and fibrosing disease associated with significant morbidity and mortality risk. Data on treatment is limited and based…
Abstract Number: 1027 • ACR Convergence 2022
Low Dose Computed Tomography Hounsfield Units: A Reliable Methodology for Assessing Changes in Vertebral Bone Density in Radiographic Axial Spondyloarthritis
Mary Lucy Marques¹, Nuno Pereira da Silva², Désirée van der Heijde³, Monique Reijnierse⁴, Juergen Braun⁵, Xenofon Baraliakos⁶, floris van Gaalen⁴ and Sofia Ramiro⁴, ¹Leiden University Medical Center, Coimbra, Portugal, ²Radiology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ³Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: In radiographic axial Spondyloarthritis (r-axSpA), low dose Computed Tomography (ldCT) Hounsfield Units (HU) were shown to cross-sectionally reliably assess bone density at each vertebra…
Abstract Number: 1350 • ACR Convergence 2022
A Prospective Study on Pain Associated with Injection of Needles: PAIN Study
Chay Bae¹, Eugenia Chen¹ and Maida Wong², ¹Rheumatology, University of California, Irvine School of Medicine, Irvine, CA, ²Rheumatology, VA Long Beach Healthcare System, Long Beach, CA
Background/Purpose: Joint pain is a common issue amongst patients. In the appropriate clinical setting, joint injections or aspirations may benefit the patient. Pain, however, is…
Abstract Number: 1635 • ACR Convergence 2022
Safety Profile of Hydroxychloroquine in a Large Cohort of Rheumatology Patients Within the US Department of Defense Military Healthcare System
Toni Rush¹, Rachel Robbins², Angelique Collamer² and Jess Edison³, ¹Health Research Tx, Trevose, PA, ²Walter Reed National Military Medical Center, Bethesda, MD, ³Uniformed Services University of the Health Sciences / National Capital Consortium- Walter Reed Bethesda, Bethesda, MD
Background/Purpose: Hydroxychloroquine (HCQ) is a well-established conventional synthetic DMARD for many rheumatologic conditions. While generally believed to be safe, HCQ use is associated with a…
Abstract Number: 2018 • ACR Convergence 2022
Five Year Follow-up of Systemic Disease Activity Measured with the ESSDAI in a Standard of Care Cohort of Patients with Primary Sjögren’s Syndrome
Liseth de Wolff¹, Suzanne Arends², Alja Stel³, Greetje van Zuiden³, Jolien van Nimwegen², Arjan Vissink⁴, Frans Kroese², Gwenny Verstappen² and Hendrika Bootsma², ¹UMCG, Zwolle, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, ⁴University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose: The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is often used as primary endpoint in randomised clinical trials (RCTs) in patients with primary Sjögren's…
Abstract Number: 2238 • ACR Convergence 2022
Performance of the 2016 ACR/EULAR Myositis Response Criteria in Adult Dermatomyositis and Polymyositis Therapeutic Trials and Consensus Profiles
Didem Saygin¹, Hanna Kim², Christian Douglas³, Brian Erman³, Jesse Wilkerson³, john mcgrath³, Chester Oddis⁴, Ingrid Lundberg⁵, Anthony Amato⁶, Ignacio Garcia-De La Torre⁷, Hector Chinoy⁸, David Fiorentino⁹, Lorinda Chung⁹, Yeong-Wook Song¹⁰, Katalin Danko¹¹, Frederick Miller¹², Nicola Ruperto¹³, Jiří Vencovský¹⁴, Rohit Aggarwal¹⁵ and Lisa G Rider¹², ¹University of Chicago, Chicago, IL, ²Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ³Social and Scientific Systems, Inc., Durham, NC, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁶Harvard University, Boston, MA, ⁷Centro de Est. de Inv. Bas. y Clinica, S.C., Guadalajara, Mexico, ⁸The University of Manchester, Sale, United Kingdom, ⁹Stanford University, Stanford, CA, ¹⁰Seoul National University, Seoul, Republic of Korea, ¹¹*Deceased, Debrecen, Hungary, ¹²Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD, ¹³IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy, ¹⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹⁵Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The ACR/EULAR myositis response criteria (MRC) were developed as a composite continuous measure (Total Improvement Score (TIS)) using absolute percent changes (abs%) in 6…
Abstract Number: 0362 • ACR Convergence 2021
Achievement of Stringent Thresholds of Disease Control Is Associated with Reduced Burden on Work and Household Productivity in Patients with Axial Spondyloarthritis
Martin Rudwaleit¹, Pedro Machado², Lianne Gensler³, Vanessa Taieb⁴, Natasha de Peyrecave⁵, Bengt Hoepken⁶ and Désirée van der Heijde⁷, ¹University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ²Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ³Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands
Background/Purpose: Axial spondyloarthritis (axSpA) is associated with increased absence from work and reduced work productivity, which can impact employment status.1 TNF inhibitors such as certolizumab…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].